Chemomab Therapeutics Ltd.

NasdaqCM:CMMB

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Israel

Market Cap

USD 23.38 M

Share Price

USD 1.20

Avg Daily Volume

130,882

Change (1 day)

-1.64%

Change (1 year)

29.03%

Change (YTD)

-33.70%

Chemomab Therapeutics Ltd. Depreciation And Amortization for the Trailing 12 Months (TTM) ending December 31, 2024

Chemomab Therapeutics Ltd. Depreciation And Amortization is NA for the Trailing 12 Months (TTM) ending December 31, 2024. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.

Chemomab Therapeutics Ltd. Depreciation And Amortization for the Trailing 12 Months (TTM) ending December 31, 2023 was USD 67.11 K, a 15.71% change year over year.
Chemomab Therapeutics Ltd. Depreciation And Amortization for the Trailing 12 Months (TTM) ending December 31, 2022 was USD 58.00 K, a 70.59% change year over year.
Chemomab Therapeutics Ltd. Depreciation And Amortization for the Trailing 12 Months (TTM) ending December 31, 2021 was USD 34.00 K, a 41.67% change year over year.
Chemomab Therapeutics Ltd. Depreciation And Amortization for the Trailing 12 Months (TTM) ending December 31, 2020 was USD 24.00 K.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Depreciation And Amortization	Dividends Paid	Common Stock Issued	Common Stock Repurchased

NasdaqCM: CMMB

Chemomab Therapeutics Ltd.

CEO	Dr. Adi Mor George Ph.D.
IPO Date	Feb. 12, 2019
Location	Israel
Headquarters	Building 7
Employees	20
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.